EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study

Rocío Corrales-Millán, Juan Maza-Solano, Juan Ramón Benito-Navarro, Virginia García-García, María José Gámiz-Maroto, Juan Andrés Márquez-Moyano, Lucía Prieto Sánchez de la Puerta, Andrés Caballero-García, Dionisio Guillamón-Fernández, Manuel Ortiz-Rueda, Dolores Alonso-Blanco, Isabel María Reyes-Tejero und 3 weitere

European Archives of Oto-Rhino-Laryngology · 2026-08 · 283 (8) · 5089-5102

DOI: 10.1007/s00405-026-10317-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 01.06.2026. Verfasst von Rocío Corrales-Millán und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and Skull Base Unit, Department of Otorhinolaryngology, University Hospital Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 , Seville, S…. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the real-world effectiveness of mepolizumab in patients with severe,uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), assessing its impacton sinonasal symptoms, endoscopic findings, asthma control, systemic corticosteroiduse, and quality of life (QoL) over 12 months. METHODS: RINOSUR 2.0 was a prospective multicenter cohort study conducted in southernSpain. Ninety-six adult patients with severe, uncontrolled bilateral CRSwNP receivedmepolizumab as add-on therapy and were followed for 12 months. Outcomes wereassessed at baseline, 6, and 12 months. Primary endpoints included the 22-itemSinonasal Outcome Test (SNOT-22), visual analogue scale (VAS) symptom scores,and Nasal Polyp Score (NPS). Asthma control was evaluated using the Asthma ControlTest (ACT). Health utility was derived from SNOT-22 using a validated mappingalgorithm to estimate quality-adjusted life years (QALYs). RESULTS: Mean SNOT-22 improved from 65.2 + 19.9 at baseline to 29.9 + 19.7 at 12 months(change -35.3; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsAntibodies, Monoclonal, HumanizedSinusitisRhinitisHumansMaleFemaleChronic DiseaseQuality of LifeMiddle AgedAdultProspective StudiesTreatment OutcomeSeverity of Illness IndexAsthma

Stichwörter der Autor:innen

Asthma controlChronic Rhinosinusitis with Nasal PolypsMepolizumabNasal polypsQuality-adjusted life years

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Rhinology and Skull Base Unit, Department of Otorhinolaryngology, University Hospital Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 , Seville, Spain. dra.rociocorrales@gmail.com.
  • Rhinology and Skull Base Unit, Department of Otorhinolaryngology, University Hospital Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 , Seville, Spain. juanm.maza.sspa@juntadeandalucia.es.
  • Department of Surgery, University of Seville, Seville, Spain. juanm.maza.sspa@juntadeandalucia.es.
  • QUIRONSALUD Sagrado Corazón Hospital, Seville, Spain. juanm.maza.sspa@juntadeandalucia.es.
  • Rhinology Study Group of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France. juanm.maza.sspa@juntadeandalucia.es.
  • Rhinology and Skull Base, Department of Otorhinolaryngology, University Hospital de Puerto Real, Cádiz, Spain.

Zitieren

APA

Corrales-Millán, R., Maza-Solano, J., Benito-Navarro, J. R., García-García, V., Gámiz-Maroto, M. J., Márquez-Moyano, J. A., de la Puerta, L. P. S., Caballero-García, A., Guillamón-Fernández, D., Ortiz-Rueda, M., Alonso-Blanco, D., Reyes-Tejero, I. M., Loaiza-Garreton, J. P., Müller-Locatelli, N., & Cuvillo-Bernal, A. (2026). Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study. European Archives of Oto-Rhino-Laryngology, 283(8), 5089-5102. https://doi.org/10.1007/s00405-026-10317-6

Vancouver

Corrales-Millán R, Maza-Solano J, Benito-Navarro JR, García-García V, Gámiz-Maroto MJ, Márquez-Moyano JA, et al. Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study. European Archives of Oto-Rhino-Laryngology. 2026;283(8):5089-5102. doi:10.1007/s00405-026-10317-6

BibTeX
@article{CorralesMilln2026,
  author = {Corrales-Millán, Rocío and Maza-Solano, Juan and Benito-Navarro, Juan Ramón and García-García, Virginia and Gámiz-Maroto, María José and Márquez-Moyano, Juan Andrés and de la Puerta, Lucía Prieto Sánchez and Caballero-García, Andrés and Guillamón-Fernández, Dionisio and Ortiz-Rueda, Manuel and Alonso-Blanco, Dolores and Reyes-Tejero, Isabel María and Loaiza-Garreton, Jean Paul and Müller-Locatelli, Nicolás and Cuvillo-Bernal, Alfonso},
  title = {Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  volume = {283},
  number = {8},
  pages = {5089--5102},
  doi = {10.1007/s00405-026-10317-6}
}
Kostenlos starten →